.Pharmacolibrary.Drugs.C_CardiovascularSystem.C01C_CardiacStimulantsExclCardiacGlycosides.C01CE02_Milrinone.Milrinone .Pharmacolibrary.Drugs.C_CardiovascularSystem.C01C_CardiacStimulantsExclCardiacGlycosides.C01CE02_Milrinone.Milrinone| name: | Milrinone |
| ATC code: | C01CE02 | route: | intravenous |
| n-compartments | 2 |
Milrinone is a phosphodiesterase 3 inhibitor used mainly for the short-term treatment of acute decompensated heart failure and for patients with severe heart failure unresponsive to conventional therapy. It produces positive inotropic and vasodilatory effects. Milrinone is approved and utilized in hospital settings, particularly in intensive care.
Pharmacokinetic parameters reported in adult patients with congestive heart failure after intravenous administration.
Hornik, CP, et al., & Gonzalez, D (2019). Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents. Journal of clinical pharmacology 59(12) 1606–1619. DOI:10.1002/jcph.1499 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31317556
Commander, SJ, et al., & Hornik, CP (2022). The relationship between simulated milrinone exposure and hypotension in children. Cardiology in the young 32(5) 782–788. DOI:10.1017/S1047951121003103 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34350821
Pellicer, A, et al., & Cabañas, F (2013). Phase 1 study of two inodilators in neonates undergoing cardiovascular surgery. Pediatric research 73(1) 95–103. DOI:10.1038/pr.2012.154 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23138399